Funds › Jones Hill Capital LP
Jones Hill Capital LP
13F for Q3 2026, filed Nov 13, 2026. 33 positions worth $589.2M.Managers with more than $100 million in US-listed stocks list their holdings each quarter, within 45 days of quarter end. Long positions only: no short sales or cash.
Ask your AI about this
Connect Claude, ChatGPT, Gemini or Grok (Microsoft 365 Copilot coming soon) to 13F.ai and ask in plain English. Copy a question to get started:
Using 13F.ai, what are the biggest new, added, trimmed and exited positions of Jones Hill Capital LP in the latest 13F quarter?
Using 13F.ai, how has Jones Hill Capital LP's portfolio concentration changed over the last four quarters?
Using 13F.ai, which of Jones Hill Capital LP's top holdings have also been bought by insiders recently?
Connect your AI · Plans and the 7-day free trial (card required)
Holdings, Q3 2026
Largest first. Common shares only.
| # | The fund's own figures at the end of the quarter. A report can be up to 45 days old when it is filed. Options and bonds are not counted here. | Filing | ||||
|---|---|---|---|---|---|---|
| 1 | BMRN BioMarin Pharmaceutical Inc. | 1.17M | $70.3M | 11.9% | -18.1% | 13F ↗ |
| 2 | BCRX BioCryst Pharmaceuticals, Inc. | 7.08M | $59.0M | 10.0% | New | 13F ↗ |
| 3 | TVTX Travere Therapeutics, Inc. | 959,634 | $56.5M | 9.6% | New | 13F ↗ |
| 4 | INDV Supernus, Inc. | 1.53M | $54.7M | 9.3% | New | 13F ↗ |
| 5 | PHVS Pharvaris N.V. | 987,637 | $31.3M | 5.3% | +45.7% | 13F ↗ |
| 6 | CELC Celcuity Inc. | 382,901 | $30.4M | 5.2% | New | 13F ↗ |
| 7 | IONS Ionis Pharmaceuticals, Inc. | 599,826 | $26.8M | 4.5% | New | 13F ↗ |
| 8 | SUPN Supernus Pharmaceuticals | 601,685 | $25.9M | 4.4% | New | 13F ↗ |
| 9 | NUVB Nuvation Bio Inc. | 4.49M | $25.1M | 4.3% | New | 13F ↗ |
| 10 | VERA Vera Therapeutics, Inc. | 652,218 | $21.1M | 3.6% | New | 13F ↗ |
| 11 | TRVI Trevi Therapeutics, Inc. | 1.45M | $20.7M | 3.5% | +8.1% | 13F ↗ |
| 12 | BCAX Bicara Therapeutics Inc. | 1.06M | $19.8M | 3.4% | +19.2% | 13F ↗ |
| 13 | RLMD Relmada Therapeutics, Inc. | 5.24M | $19.7M | 3.4% | +43.3% | 13F ↗ |
| 14 | ABVX Abivax SA · ADR | 142,558 | $14.1M | 2.4% | New | 13F ↗ |
| 15 | ACRS Aclaris Therapeutics, Inc. | 2.50M | $13.2M | 2.2% | +42.4% | 13F ↗ |
| 16 | INSM Insmed Incorporated · Com Par $.01 | 106,528 | $12.2M | 2.1% | -12.9% | 13F ↗ |
| 17 | NBIX Neurocrine Biosciences, Inc. | 83,426 | $11.8M | 2.0% | New | 13F ↗ |
| 18 | IMCR Immunocore Holdings plc · ADR | 384,278 | $11.6M | 2.0% | -25.1% | 13F ↗ |
| 19 | ERAS Erasca, Inc. | 610,118 | $8.9M | 1.5% | New | 13F ↗ |
| 20 | CAPR Capricor Therapeutics, Inc. | 892,532 | $8.5M | 1.4% | +112% | 13F ↗ |
| 21 | DNTH Dianthus Therapeutics, Inc. | 80,017 | $7.0M | 1.2% | +40.1% | 13F ↗ |
| 22 | NGNE Neurogene Inc. | 217,700 | $6.1M | 1.0% | New | 13F ↗ |
| 23 | CRBP Corbus Pharmaceuticals Holdings, Inc. | 886,428 | $6.0M | 1.0% | +35.6% | 13F ↗ |
| 24 | TNXP Tonix Pharmaceuticals Holding Corp. | 563,739 | $5.5M | 0.9% | -9.9% | 13F ↗ |
| 25 | SGMT Sagimet Biosciences Inc. | 502,587 | $5.0M | 0.8% | New | 13F ↗ |
| 26 | DYN Dyne Therapeutics, Inc. | 300,900 | $4.8M | 0.8% | New | 13F ↗ |
| 27 | AVLN Avalyn Pharma Inc. | 126,744 | $3.6M | 0.6% | New | 13F ↗ |
| 28 | ATTO Attovia Therapeutics, Inc. | 182,295 | $3.1M | 0.5% | New | 13F ↗ |
| 29 | PHAT Phathom Pharmaceuticals, Inc. | 276,830 | $2.0M | 0.3% | +71.4% | 13F ↗ |
| 30 | LXEO Lexeo Therapeutics, Inc. | 593,737 | $2.0M | 0.3% | New | 13F ↗ |
| 31 | OLMA Olema Oncology, Inc. | 206,397 | $1.8M | 0.3% | -64.1% | 13F ↗ |
| 32 | TENX Tenax Therapeutics, Inc. | 122,169 | $230.9K | <0.1% | New | 13F ↗ |
| 33 | ALVO Alvotech | 26,700 | $154.9K | <0.1% | New | 13F ↗ |
Changes since Q2 2026
19 new, 9 added to, 5 trimmed, 15 exited, 0 unchanged. By estimated dollars.
New positions (19)
| BCRX BioCryst Pharmaceuticals, Inc. | 7.08M | New | $59.0M |
| TVTX Travere Therapeutics, Inc. | 959,634 | New | $56.5M |
| INDV Supernus, Inc. | 1.53M | New | $54.7M |
| CELC Celcuity Inc. | 382,901 | New | $30.4M |
| IONS Ionis Pharmaceuticals, Inc. | 599,826 | New | $26.8M |
| SUPN Supernus Pharmaceuticals | 601,685 | New | $25.9M |
| NUVB Nuvation Bio Inc. | 4.49M | New | $25.1M |
| VERA Vera Therapeutics, Inc. | 652,218 | New | $21.1M |
| ABVX Abivax SA · ADR | 142,558 | New | $14.1M |
| NBIX Neurocrine Biosciences, Inc. | 83,426 | New | $11.8M |
Added to (9)
| PHVS Pharvaris N.V. | 987,637 | +45.7% | $9.8M |
| RLMD Relmada Therapeutics, Inc. | 5.24M | +43.3% | $6.0M |
| CAPR Capricor Therapeutics, Inc. | 892,532 | +112% | $4.5M |
| ACRS Aclaris Therapeutics, Inc. | 2.50M | +42.4% | $3.9M |
| BCAX Bicara Therapeutics Inc. | 1.06M | +19.2% | $3.2M |
| DNTH Dianthus Therapeutics, Inc. | 80,017 | +40.1% | $2.0M |
| CRBP Corbus Pharmaceuticals Holdings, Inc. | 886,428 | +35.6% | $1.6M |
| TRVI Trevi Therapeutics, Inc. | 1.45M | +8.1% | $1.5M |
| PHAT Phathom Pharmaceuticals, Inc. | 276,830 | +71.4% | $842.0K |
Trimmed (5)
Exited (15)
| GILD Gilead Sciences, Inc. | 343,043 | Exited | -$43.3M |
| ARQT Arcutis Biotherapeutics, Inc. | 1.09M | Exited | -$28.6M |
| MDGL Madrigal Pharmaceuticals, Inc. | 52,545 | Exited | -$28.2M |
| XENE Xenon Pharmaceuticals Inc. | 367,900 | Exited | -$22.2M |
| ANIP ANI Pharmaceuticals, Inc. | 233,808 | Exited | -$19.4M |
| AMLX Amylyx Pharmaceuticals, Inc. | 894,058 | Exited | -$16.1M |
| Nuvalent Inc | 98,442 | Exited | -$12.2M |
| IMUX Immunic, Inc. | 539,814 | Exited | -$8.3M |
| ORIC Oric Pharmaceuticals, Inc. | 747,313 | Exited | -$8.1M |
| SNDX Syndax Pharmaceuticals, Inc. | 340,000 | Exited | -$7.4M |
The 10 largest of each, by estimated dollars: shares changed times the later report's price. Index tracking, splits and mergers move positions too.
Compare two quarters
Pick any two quarters: what is new, added to, trimmed or exited. Premium plan.
Reported value by quarter
Value and number of positions at the end of each quarter.
Loading…
Largest positions in earlier quarters
Pick a quarter to see what the fund's biggest positions were then.
Loading…
Ten largest positions
By value, Q3 2026.
Filings
Most recent first, up to 80. An amendment can replace a report or add holdings to it. All 13F filings
Information, not investment advice. Values are the fund's own figures at quarter end; a report can be up to 45 days old when filed. Disclaimer